ESMO 2026: Key lung cancer highlights
Emerging treatment strategies in SCLC and NSCLC
Review key updates in small-cell lung cancer (SCLC) and non–small-cell lung cancer (NSCLC) presented at the European Society for Medical Oncology (ESMO) Congress 2026. Our congress coverage examines emerging data across first-line, maintenance, and previously treated disease settings, including advances in KRAS-targeted therapy, DLL3-targeted approaches, and immunotherapy-based treatment strategies. Key topics include:
- New insights into tarlatamab for extensive-stage SCLC (ES-SCLC)
- Highlights in KRAS-mutated NSCLC
- Outcomes with serplulimab and atezolizumab from the ASTRIDE trial in ES-SCLC
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors, Amgen and Astellas, which have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsors in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.